28.57
12.08%
+3.08
Handel nachbörslich:
28.70
0.13
+0.46%
Schlusskurs vom Vortag:
$25.49
Offen:
$27
24-Stunden-Volumen:
1.52M
Marktkapitalisierung:
$2.19B
Einnahmen:
$937.82M
Nettoeinkommen (Verlust:
$-626.60M
KGV:
-3.3029
EPS:
-8.65
Netto-Cashflow:
$-279.04M
1W Leistung:
+12.84%
1M Leistung:
+2.18%
6M Leistung:
+19.29%
1J Leistung:
-45.31%
PTC Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
PTC Therapeutics Inc
Sektor
Branche
Telefon
908-222-7000
Adresse
100 Corporate Court, South Plainfield, NJ
PTC Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
2023-10-06 | Herabstufung | Truist | Buy → Hold |
2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
2022-12-14 | Eingeleitet | Goldman | Sell |
2022-09-12 | Eingeleitet | Jefferies | Buy |
2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
2022-09-01 | Eingeleitet | Citigroup | Buy |
2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
2020-10-28 | Eingeleitet | UBS | Neutral |
2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
2020-08-25 | Eingeleitet | Raymond James | Outperform |
2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2019-11-12 | Eingeleitet | SunTrust | Buy |
2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
2019-04-11 | Eingeleitet | Bernstein | Outperform |
2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
PTC Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Zacks Investment Research
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
Zacks Investment Research
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Benzinga
Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings
Zacks Investment Research
Finanzdaten der PTC Therapeutics Inc-Aktie (PTCT)
PTC Therapeutics Inc (PTCT) Umsatz 2024
PTCT meldete einen Umsatz der letzten 12 Monate von 937.82 Millionen US-Dollar für das Quartal zum 2023-12-31, was einem Anstieg von +34.20% im Vergleich zum Vorjahr entspricht.
PTC Therapeutics Inc (PTCT) Nettogewinn 2024
PTCT betrug am 2023-12-31 der Nettogewinn der letzten 12 Monate -626.60 Millionen US-Dollar, was einem Rückgang von -12.09% im Vergleich zum Vorjahr entspricht.
PTC Therapeutics Inc (PTCT) Free Cashflow 2024
PTCT verzeichnete einen Free Cashflow der letzten 12 Monate von -279.04 Millionen US-Dollar für das Quartal bis zum 2023-12-31, was einem Anstieg von +45.19% im Vergleich zum Vorjahr entspricht.
PTC Therapeutics Inc (PTCT) Gewinn je Aktie 2024
Der Gewinn je Aktie (EPS) von PTCT für die letzten 12 Monate betrug -8.36 US-Dollar für das Quartal, das am 2023-12-31 endete, was einem Rückgang von -7.32% im Vergleich zum Vorjahr entspricht.
PTC Therapeutics Inc-Aktie (PTCT) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Apr 17 '24 |
Sale |
25.14 |
1,307 |
32,851 |
229,168 |
Pauwels Eric | CHIEF EXECUTIVE OFFICER |
Apr 17 '24 |
Sale |
25.14 |
787 |
19,781 |
67,694 |
Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Apr 02 '24 |
Sale |
28.37 |
526 |
14,923 |
59,988 |
Boulding Mark Elliott | EXEC. VP AND CLO |
Jan 30 '24 |
Sale |
27.25 |
794 |
21,637 |
71,189 |
Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 30 '24 |
Sale |
27.25 |
618 |
16,841 |
61,202 |
Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 30 '24 |
Sale |
27.25 |
366 |
9,974 |
44,181 |
Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER |
Jan 30 '24 |
Sale |
27.25 |
318 |
8,666 |
35,528 |
Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 30 '24 |
Sale |
27.25 |
28 |
763 |
3,706 |
Jacobson Allan Steven | Director |
Jan 22 '24 |
Option Exercise |
27.05 |
10,000 |
270,500 |
22,348 |
Jacobson Allan Steven | Director |
Jan 22 '24 |
Sale |
27.38 |
10,000 |
273,804 |
12,348 |
Kapitalisierung:
|
Volumen (24h):